Ovarian cancer vaccine - Onyvax/Mayo Clinic
Alternative Names: Onyvax-O; OnyvaxOLatest Information Update: 02 Oct 2021
At a glance
- Originator Mayo Clinic; Onyvax
- Developer Onyvax
- Class Cancer vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 10 Dec 2007 Preclinical development is ongoing
- 15 Jan 2004 Preclinical trials in Ovarian cancer in United Kingdom (unspecified route)